What happened
- A clinical trial raised questions about how to decide who should take statins to prevent heart attacks and strokes.
- Researchers found that using heart scans to guide treatment produced the same observed rate of major cardiovascular events as traditional risk assessment, even though it led to recommending statins to far fewer people.
- Those advised according to calcium buildup in coronary arteries followed their treatment substantially more consistently.
- The results were presented in a Hot Line session at ESC Congress 2026, and ScienceDaily circulated them on 6 November 2026.
- The trial did not establish that the scan approach is as effective as conventional assessment.
Why it matters
Statins are among the widely prescribed drugs, and deciding to prescribe them to people without heart disease depends on a risk calculation. If an imaging test lets fewer people be treated without losing prevented events, unnecessary use and side effects fall. Adherence is a result in itself: seeing calcium in one’s own arteries seems to motivate staying on treatment.
The number
Same rate, fewer recommendations. The scan-guided group had the same observed major event rate with far fewer statin recommendations; authors call for more studies to confirm equivalence to the conventional strategy.
Context
Atherosclerotic cardiovascular disease develops when fatty plaque builds up in arteries and restricts blood flow, and it is the world’s leading cause of illness and death. The text read gives neither participant numbers nor follow-up length, so statistical power to detect differences cannot be assessed. “Same” in a trial is not “non-inferior”: that needs a design built to show it, which the authors acknowledge. Related coverage: More free DNA in the blood improves early cancer detection instead of diluting it, A PET scan with a labelled amino acid detects 91% of glioblastoma, against 53% for MRI, Roche tests RO3903, a KRAS G12C inhibitor that sidesteps resistance in mice, A method estimates the resilience of Earth systems with seasonality and irregular data.
What’s next
- Studies designed to show equivalence or superiority of the scan approach are expected.
- Cardiovascular guidelines may weigh including the coronary calcium score.
- Costs and access to scanning in different health systems will need measuring.
Bottom line
Prescribing to fewer people with the same outcomes would be progress, but first it must be shown the outcomes really are the same.
Sources
- ScienceDaily, “Major trial challenges how doctors decide who really needs statins”, 6 November 2026, on a trial presented at ESC Congress 2026. The original presentation was not read.
- Cover image: Alaa Najjar, CC BY-SA 3.0, via Wikimedia Commons
Edited by Rodrigo Cornejo. How we select and verify: who writes these notes.
